Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest.
暂无分享,去创建一个
T. Sundt | N. Kouchoukos | J. Saffitz | T. H. Wareing | S. Murphy | D. Stahl | J. E. Saffitz | David J. Stahl
[1] S. Westaby. Aprotinin in perspective. , 1993, The Annals of thoracic surgery.
[2] F. Loop,et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. , 1992, The Annals of thoracic surgery.
[3] A. Griesmacher,et al. Aprotinin decreases release of 6-keto-prostaglandin F1 alpha and increases release of thromboxane B2 in cultured human umbilical vein endothelial cells. , 1992, The Journal of thoracic and cardiovascular surgery.
[4] M. Yacoub,et al. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. , 1992, The Journal of thoracic and cardiovascular surgery.
[5] W. Vanoeveren,et al. Anticoagulation policy during use of aprotinin in cardiopulmonary bypass. , 1992 .
[6] W. Dietrich,et al. High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. , 1992, Journal of cardiothoracic and vascular anesthesia.
[7] D. Royston. High-dose aprotinin therapy: a review of the first five years' experience. , 1992, Journal of cardiothoracic and vascular anesthesia.
[8] L. V. von Segesser,et al. Low-dose aprotinin also allows reduction of blood loss after cardiopulmonary bypass. , 1991, The Journal of thoracic and cardiovascular surgery.
[9] R. Colman,et al. Invited letter concerning: aprotinin. , 1991, The Journal of thoracic and cardiovascular surgery.
[10] W. van Oeveren,et al. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. , 1991, The Annals of thoracic surgery.
[11] H. Teufelsbauer,et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. , 1991, The Journal of thoracic and cardiovascular surgery.
[12] J. E. Doran,et al. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. , 1991, The Journal of thoracic and cardiovascular surgery.
[13] W. van Oeveren,et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin. , 1990, The Journal of thoracic and cardiovascular surgery.
[14] W. van Oeveren,et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. , 1990, The Journal of thoracic and cardiovascular surgery.
[15] J. Griffin,et al. Aprotinin (trasylol) is a competitive inhibitor of activated protein C. , 1989, Thrombosis research.
[16] T. Emerson. Pharmacology of Aprotinin and Efficacy During Cardiopulmonary Bypass , 1989 .
[17] D. Cosgrove,et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). , 1989, The Journal of thoracic and cardiovascular surgery.
[18] W. van Oeveren,et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. , 1987, The Annals of thoracic surgery.
[19] D. Lane,et al. The neutralisation of heparin by Trasylol. , 1980, Thrombosis research.
[20] J. Salaman,et al. TRASYLOL (APROTININ) AND KIDNEY PRESERVATION , 1978, Transplantation.
[21] H. Nagaoka,et al. Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. , 1991, The Journal of cardiovascular surgery.
[22] Fischer Jh,et al. Aprotinin (Trasylol) protection--unsuitable for hypothermic kidney preservation. , 1984 .